ArticleFrontiers in pediatrics2022
D-dimer: The Risk Factor of Children's Severe Mycoplasma Pneumoniae Pneumonia.
Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 43 citations in OpenAlex.
- Assessment of predictive efficacy for prognosis of pediatric severeTranslational pediatrics · 2026Article
- Risk factors for plastic bronchitis complicating severeTranslational pediatrics · 2026Article
- S100A8/A9 as a novel predictor for severe Mycoplasma pneumoniae pneumonia in children: A prospective observational study.Clinics (Sao Paulo, Brazil) · 2026Article
- Utility of a Combined Diagnostic and Severity Scoring System Based on Complete Blood Count and Derived Immune-Inflammatory Indicators in Children With Mycoplasma pneumoniae Pneumonia.Journal of clinical laboratory analysis · 2026Article
- East Asia as a sentinel: risk-stratified corticosteroid therapy for paediatric macrolide-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- Oral pentoxifylline as a novel adjunct to standard therapy in pediatric community-acquired pneumonia: a randomized controlled trial.Pediatric research · 2026Article
- Correlation analysis of FABP3, MCP-4, and CXCL9 levels and myocardial damage in patients with severe pneumonia.Journal of medical biochemistry · 2026Article
- A retrospective clinical risk prediction model for co‑infection with Mycoplasma pneumoniae in patients with COVID‑19 based on restricted cubic splines.Scientific reports · 2026Article
- Predicting macrolide resistance in pediatric Mycoplasma pneumoniae pneumonia: A machine learning modeling study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Comparison of severe and general Mycoplasma pneumoniae pneumonia in children: a targeted next-generation sequencing based study.BMC infectious diseases · 2026Article
- Development and validation of a predictive nomogram for ventilator-associated pneumonia in patients with traumatic brain injury: based on the MIMIC-IV database.Journal of thoracic disease · 2026Article
- Peripheral blood inflammatory cytokines linked to clinical outcomes inMicrobiology spectrum · 2026Article
- Factors associated with pulmonary embolism in children with refractoryFrontiers in pediatrics · 2026Article
- Clinical value of neutrophil-to-lymphocyte ratio and D-dimer in predicting the efficacy of minocycline for pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Host inflammatory markers and MLVA profiling for risk assessment of severe pediatricFrontiers in cellular and infection microbiology · 2026Article
- Serum HMGB3 and PCSK9 Levels as Predictors of Early Treatment Response in PediatricInternational journal of general medicine · 2026Article
- Development of a Prediction Model for Severe PediatricInfection and drug resistance · 2026Article
- CT-based radiomics models for predicting the prognosis of children with mycoplasma pneumonia.Frontiers in cellular and infection microbiology · 2026Article
- Nomogram to predict severeFrontiers in pediatrics · 2026Article
- Influence of Mycoplasma Resistance Genes on Pediatric Mycoplasma Pneumonia Treatment and Determinants for Second-line Antimicrobial Adjustment.Combinatorial chemistry & high throughput screening · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Mycoplasma Pneumoniae (MP) is an important cause of community-acquired pneumonia in children, which can cause serious consequences. There has been some research into predicting Severe Mycoplasma Pneumoniae Pneumonia (SMPP) primarily focused on pre-treatment time by macrolide, pre-hospital course, CRP and LDH et.al. while seldom reporting on concoagulation status. We designed this retrospective study to compare the difference between SMPP and Non-severe MPP (NSMPP) with an attempt to find the risk factors, with a special focus on concoagulation status. Method: We performed a retrospective study of 786 MPP patients who were hospitalized from January 1, 2016 to December 31, 2018, age ranging from 28 days to 18 years old. All patients were divided into SMPP group and NSMPP group. A univariate analysis was conducted between both groups. The factors with statistical differences were included in logistic regression analysis to summarize the predictors of SMPP. Next, the predictive value of each risk factor was calculated from the receiver operating characteristic curve (ROC curve). Patients who had D-dimer records were divided into the elevated D-dimer group (D-dimer > 308ug/L) and the control group (D-dimer ≤ 308ug/L), and the clinical manifestations were compared. Results: There was no significant difference in gender, age, pre-treatment time by macrolide, the white blood cell counts (WBC), Fibrinogen (FIB), Activated Partial Prothrombin Time (APTT), Prothrombin Time (PT) and Thrombin Time (TT) between SMPP and NSMPP. Compared with NSMPP, the pre-hospital course of SMPP was longer ( Conclusion: The N%, PLT, CRP, LDH and D-dimer were risk factors for SMPP. D-dimer was the best predictor among them. MPP patients with D-dimer > 308ug/L had more complications such as pleural effusion, myocardial and liver damage. More attention should be given in the treatment for this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.